Jufeng Wang

机构：Zhengzhou University, Henan Cancer Hospital, Affiliated Hospital of Jining Medical University · ORCID：0000-0002-5933-2152

发表论文 91 篇 · 总被引 1971 次 · h-index 26

代表论文

• First-Line Sugemalimab Plus Chemotherapy for Advanced Gastric Cancer (2025 · JAMA · 被引 71)
• First-line sugemalimab with chemotherapy for advanced esophageal squamous cell carcinoma: a randomized phase 3 study (2024 · Nature Medicine · 被引 56)
• First-in-human dose escalation and expansion study of SYSA1801, an antibody-drug conjugate targeting claudin 18.2 in patients with resistant/refractory solid tumors. (2023 · Journal of Clinical Oncology · 被引 32)
• Irinotecan hydrochloride liposome HR070803 in combination with 5-fluorouracil and leucovorin in locally advanced or metastatic pancreatic ductal adenocarcinoma following prior gemcitabine-based therapy (PAN-HEROIC-1): a phase 3 trial (2024 · Signal Transduction and Targeted Therapy · 被引 29)
• Development and validation of a deep learning model for predicting postoperative survival of patients with gastric cancer (2024 · BMC Public Health · 被引 17)
• A phase I/II study of ASKB589 (anti-claudin 18.2 [CLDN18.2] monoclonal antibody) in patients with solid tumors. (2023 · Journal of Clinical Oncology · 被引 13)